AVTE
Aerovate Therapeutics, Inc. [AVTE] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
AVTE Stock Summary
In the News
AVTE Financial details
Company Rating
-
Market Cap
703.26M
Income
-74.4M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
51
Optionable
No
Shortable
Yes
Earnings
13 May 2024
P/E
-8.15
Forward P/E
-
PEG
-2.34
P/S
-
P/B
4.47
P/C
-
P/FCF
-9.89
Quick Ratio
9.18
Current Ratio
9.34
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2.83
EPS next Y
-
EPS next Q
-
EPS this Y
36.67%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
4.23%
-
-
-
-
SMA20
7.89%
SMA50
8.9%
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-49%
ROE
-54%
ROC
-0.6%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
9.41-32.415
52W High
+193.13%
52W Low
+942.22%
RSI
58.35
Rel Volume
0.21
Avg Volume
138.58K
Volume
29.13K
Perf Week
0%
Perf Month
8.5%
Perf Quarter
-
Perf Half Y
3.08%
-
-
-
-
Beta
1.231
-
-
Volatility
1.19%, 3.51%
Prev Close
0%
Price
93.8
Change
0.37%
Company Profile
- Volume Average 138.58K
- Market Capitalization 703.26M
- Employee 51
- CEO Mr. Timothy P. Noyes M.B.A.
- Headquarters Waltham,MA,US
- IPO Date 2021-06-30
-
Website
https://aerovatetx.com 
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
